Selank dosage calculator
Enter a vial and a dose and this returns the concentration, the volume and the syringe units. Underneath it, the same arithmetic worked out in advance for common vials, and the doses published studies of Selank actually used, every one quoted and cited. It converts numbers. It does not suggest what to take.
Work out concentration and what to draw
Two divisions, both shown. Concentration = mass in the vial ÷ diluent volume. Volume to draw = mass you want ÷ that concentration. Syringe units are that volume × the units per millilitre on your syringe's own scale.
Worked example: 5 mg in 2 mL is 2,500 mcg/mL, so 250 mcg is 0.1 mL, which is 10 units on a U-100 syringe and 4 units on a U-40. The scale is printed on the barrel; reading a U-40 syringe as if it were U-100 is a two-and-a-half-fold error.
Why there is no units chart for Selank
Every dose quoted in studies of Selank is given per kilogram of body weight, and none is an absolute quantity. A chart of syringe units needs a fixed mass to work from, so there is nothing honest to put in one.
The obvious move — multiply a per-kilogram figure by a body weight — is the one thing that must not be done here. Most of these figures come from rats or mice, and dose does not scale between species by arithmetic: surface area, metabolic rate and clearance all differ, which is why interspecies conversion is a calculation with published factors and assumptions rather than a multiplication. A number produced that way would look like a dose and carry none of the evidence a dose needs.
The calculator above still works. Give it the vial and the mass you intend to draw and it returns the volume and the units. What it cannot do, for this compound, is tell you what that mass should be, because no study in this ledger states one.
Doses in published studies of Selank
Each row is quoted from a paper in this compound's source ledger and carries the kind of evidence it came from. None is a human dose: no study here administered Selank to people at a stated dose.
| Evidence | Dose as the paper states it | Source |
|---|---|---|
| Animal, preclinical | Animal study, rats, 2022: doses stated in the abstract: 0.3 mg/kg; 2 mg/kg. Single intraperitoneal injection of Selank in an anxiolytic dose of 0.3 mg/kg reduced the total index of morphine withdrawal syndrome by 39.6%, significantly (р<0.0001) attenuated convulsive reactions, ptosis, and posture disorders, and 9-fold increased the… | pmid-36322304 |
| Animal, preclinical | Animal study, rats, 2021: doses stated in the abstract: 100 mcg/kg/day. Laboratory animals were divided into 3 groups: a group of intact males, a group of animals that were subjected to stress (sensory contact) for 20 days and a group that received intraperitoneally Selank at a dose of 100 mcg/kg/day under conditions of 20-day stress. | pmid-32621722 |
| Animal, preclinical | Animal study, rats, 2019: doses stated in the abstract: 0.3 mg/kg a day. In the object recognition test, Selank (0.3 mg/kg a day, 7 days, intraperitoneally) produced a cognitive-stimulating effect in 9 months rats not exposed to ethanol (p<0.05) and prevented the formation of ethanol-induced memory and attention disturbances (p<0.01)… | pmid-31625062 |
| Animal, preclinical | Animal study, rats, 2017: doses stated in the abstract: 1000 μg/kg. Administration of Selank in a dose of 1000 μg/kg reduced the content of aminotransferases in blood serum, decreased superoxide dismutase activity in the liver, and increased total antioxidant activity. | pmid-28853100 |
| Animal, preclinical | Animal study, mice, n=2, 2016: doses stated in the abstract: 0.3 mg/kg. Selank that enhances activity of the endogenous opioid system (0.3 mg/kg, intraperitoneally), similar to the nonselective opiate receptor blocker naloxone (1.0 mg/kg, intraperitoneally), prevented the development of ethanol-induced (2.0 g/kg intraperitoneally)… | pmid-27878720 |
| Animal, preclinical | Animal study, mice, n=6, 2016: doses stated in the abstract: 300 μg/kg/day. Pharmacological effects of intraperitoneal (i.p.) and intranasal (i.n.) administration of heptapeptide selank (300 μg/kg/day for 5 days), known to possess anxiolytic and nootropic properties, were compared by studying the elevated-plus-maze behavior of inbred… | pmid-29787664 |
Weight-normalised doses, and why they are not on the chart
Some studies state a dose per kilogram. Those figures are deliberately absent from the chart above, because multiplying one by a body weight produces a number that looks like a dose and is not one. Interspecies scaling is not arithmetic: a rat milligram-per-kilogram figure does not become a human dose by multiplication.
- Animal study, rats, 2022: weight-normalized doses as published: 0.3 mg/kg; 2 mg/kg. Single intraperitoneal injection of Selank in an anxiolytic dose of 0.3 mg/kg reduced the total index of morphine withdrawal syndrome by 39.6%, significantly (р<0.0001) attenuated convulsive reactions, ptosis, and posture disorders, and 9-fold increased… pmid-36322304
- Animal study, rats, 2021: weight-normalized doses as published: 100 mcg/kg/day. Laboratory animals were divided into 3 groups: a group of intact males, a group of animals that were subjected to stress (sensory contact) for 20 days and a group that received intraperitoneally Selank at a dose of 100 mcg/kg/day under conditions of 20-day… pmid-32621722
- Animal study, rats, 2019: weight-normalized doses as published: 0.3 mg/kg a day. In the object recognition test, Selank (0.3 mg/kg a day, 7 days, intraperitoneally) produced a cognitive-stimulating effect in 9 months rats not exposed to ethanol (p<0.05) and prevented the formation of ethanol-induced memory and attention disturbances… pmid-31625062
- Animal study, rats, 2017: weight-normalized doses as published: 1000 μg/kg. Administration of Selank in a dose of 1000 μg/kg reduced the content of aminotransferases in blood serum, decreased superoxide dismutase activity in the liver, and increased total antioxidant activity. pmid-28853100
- Animal study, mice, n=2, 2016: weight-normalized doses as published: 0.3 mg/kg. Selank that enhances activity of the endogenous opioid system (0.3 mg/kg, intraperitoneally), similar to the nonselective opiate receptor blocker naloxone (1.0 mg/kg, intraperitoneally), prevented the development of ethanol-induced (2.0 g/kg… pmid-27878720
- Animal study, mice, n=6, 2016: weight-normalized doses as published: 300 μg/kg/day. Pharmacological effects of intraperitoneal (i.p.) and intranasal (i.n.) administration of heptapeptide selank (300 μg/kg/day for 5 days), known to possess anxiolytic and nootropic properties, were compared by studying the elevated-plus-maze behavior of… pmid-29787664
How long studies ran, and how far a vial goes
A vial lasts for a number of draws, not a number of weeks: divide the mass in the vial by the mass per draw and round down, which the vial planner does. How long that represents depends on frequency. For context, these are the durations studies of Selank actually ran for.
- Animal study, rats, 2021: durations stated: 20 days; 20 day. Laboratory animals were divided into 3 groups: a group of intact males, a group of animals that were subjected to stress (sensory contact) for 20 days and a group that received intraperitoneally Selank at a dose of 100 mcg/kg/day under conditions of 20-day stress. pmid-32621722
- Animal study, rats, 2019: durations stated: 30 weeks. The effects of a peptide anxiolytic Selank synthesized on the basis of the endogenous peptide tuftsin on memory impairment and content of brain-derived neurotrophic factor (BDNF) in brain structures were analyzed in outbred rats receiving 10% ethanol as the only source of fluid for… pmid-31625062
- Animal study, mice, n=6, 2016: durations stated: 5 days. Pharmacological effects of intraperitoneal (i.p.) and intranasal (i.n.) administration of heptapeptide selank (300 μg/kg/day for 5 days), known to possess anxiolytic and nootropic properties, were compared by studying the elevated-plus-maze behavior of inbred BALB/c and C57BL/6… pmid-29787664
- Animal study, rats, 2010: durations stated: 30 days. Retention was tested 24 h, 7 and 30 days after treatment. pmid-20919548
Storage and stability, as published
Reconstitution starts a clock. These are the storage and stability conditions stated in papers in this ledger. They describe what the study did, which is not the same as a shelf life for a vial in your fridge.
- Animal study, rats, 2010: It was established that selank induces an increase in memory trace stability during 30 days. pmid-20919548
- In vitro study, humans, 2001: A dose-dependent effect of synthetic heptapeptides Semax (Met-Glu-His-Phe-Pro-Gly-Pro) and Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) on the enkephalin-degrading enzymes of human serum was demonstrated. pmid-11443939
How Selank was given
The route changes what a dose means. The same number given intravenously and subcutaneously is not the same exposure.
- Animal study, rats, 2022: administration by intraperitoneal route reported. Single intraperitoneal injection of Selank in an anxiolytic dose of 0.3 mg/kg reduced the total index of morphine withdrawal syndrome by 39.6%, significantly (р<0.0001) attenuated convulsive reactions, ptosis, and posture disorders, and 9-fold increased the… pmid-36322304
- Animal study, rats, 2021: administration by intraperitoneal route reported. Laboratory animals were divided into 3 groups: a group of intact males, a group of animals that were subjected to stress (sensory contact) for 20 days and a group that received intraperitoneally Selank at a dose of 100 mcg/kg/day under conditions of 20-day stress. pmid-32621722
- Animal study, rats, 2019: administration by intraperitoneal route reported. In the object recognition test, Selank (0.3 mg/kg a day, 7 days, intraperitoneally) produced a cognitive-stimulating effect in 9 months rats not exposed to ethanol (p<0.05) and prevented the formation of ethanol-induced memory and attention disturbances (p<0.01)… pmid-31625062
- Animal study, rats, 2017: administration by intraperitoneal route reported. We studied the effect of Selank administered intraperitoneally in doses of 100, 300, and 1000 μg/kg to male Wistar rats 15 min prior to restraint stress on the content of aminotransferases and total protein concentration in blood serum and intensity of free… pmid-28853100
- Animal study, mice, n=2, 2016: administration by intraperitoneal route reported. Selank that enhances activity of the endogenous opioid system (0.3 mg/kg, intraperitoneally), similar to the nonselective opiate receptor blocker naloxone (1.0 mg/kg, intraperitoneally), prevented the development of ethanol-induced (2.0 g/kg… pmid-27878720
Questions people ask
- Does adding more diluent waste the peptide?
- No. The mass in the vial does not change. More diluent spreads the same mass through more liquid, so each dose is a larger, easier-to-measure volume and the vial yields exactly as many doses as before.
- Why does this page not recommend a dose?
- Because a dose is a clinical decision rather than a division. It depends on why someone is taking something, what else they take and how their kidneys and liver are working, none of which is knowable from a number typed into a box.
- Where do the doses in the table come from?
- Each is quoted from a specific paper indexed in Europe PMC, linked in the source column, and labelled with the kind of study it came from. The full evidence is on the Selank record.
What this calculator will not do
It will not take a body weight and return a milligram figure, and it will not tell you how often to draw. The table above is the published record, not a menu. For Selank there is no human dose in this ledger to copy even if you wanted one.
Other calculators
- Generic reconstitution calculatorThe same arithmetic, without a compound attached
- Unit convertermg, mcg, ng and syringe units
- Vial plannerDraws per vial and how long it lasts
- All compound calculatorsEvery compound with published dose figures